Dr. Millie Samaniego is a transplant nephrologist with 27 years of experience in immunopathology and clinical transplantation. Dr. Samaniego is a graduate of the University of Panama School of Medicine and continued her graduate training in Internal Medicine at Baylor College of Medicine in Houston, TX.She completed his residency in Nephrology and Immunopathology at Johns Hopkins School of Medicine, where she joined the original team of the Johns Hopkins Incompatible Kidney Transplant Program. Through this work, she gained experience in desensitization protocols, management of sensitized patients, patients with acute and chronic lesion of antibodies against transplantation, and the use of histocompatibility techniques in the clinic.Dr. Samaniego has been associate professor and professor at the University of Wisconsin and the University of Michigan, respectively; and developed desensitization programs at both institutions. During her tenure at the University of Michigan, she was the first Alan B. Leichtman Collegiate Chair of Transplant Nephrology.Dr. Samaniego has been medical director of two kidney and pancreas transplant programs: the University of Michigan from 2009 to 2017 and the Henry Ford Transplant Institute from 2018-2022. She has been co-principal investigator on several NIH consortia proposals, including GoCAR (PO1), CTOT-09, CTOT-19, and CTOT-21; and co-investigator in many pharmaceutical industry studies. Dr. Samaniego has been an associate editor of the American Journal of Transplantation and is an ad-hoc reviewer in many nephrology and transplant journals. She has held leadership roles in the ASN, AST, NKF and TTS. She is the author of more than 100 original manuscripts and has been a guest speaker at many national and international meetings.